Cargando…
The Effects of Second Primary Malignancies and Frailty on Overall Survival and Mortality in Geriatric Turkish Patients with Multiple Myeloma
The study aims to investigate second primary malignancy (SPM) development and frailty in Turkish geriatric patients with multiple myeloma (MM) and to assess the relationship between overall survival (OS) and various characteristics including SPM and frailty. Seventy-two patients diagnosed with and t...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297070/ https://www.ncbi.nlm.nih.gov/pubmed/37366906 http://dx.doi.org/10.3390/curroncol30060423 |
_version_ | 1785063796456292352 |
---|---|
author | Ipek, Yildiz Karademir, Nevra Yilmazer, Onur Yilmaz, Guven |
author_facet | Ipek, Yildiz Karademir, Nevra Yilmazer, Onur Yilmaz, Guven |
author_sort | Ipek, Yildiz |
collection | PubMed |
description | The study aims to investigate second primary malignancy (SPM) development and frailty in Turkish geriatric patients with multiple myeloma (MM) and to assess the relationship between overall survival (OS) and various characteristics including SPM and frailty. Seventy-two patients diagnosed with and treated for MM were enrolled in the study. Frailty was determined by the IMWG Frailty Score. Fifty-three participants (73.6%) were found to have clinically-relevant frailty. Seven patients (9.7%) had SPM. Median follow-up was 36.5 (22–48.5) months, and 17 patients died during the follow-up period. Overall (OS) was 49.40 (45.01–53.80) months. Shorter OS was found in patients with SPM (35.29 (19.66–50.91) months) compared to those without (51.05 (46.7–55.4) months) (Kaplan–Meier; p = 0.018). The multivariate cox proportional hazards model revealed that patients with SPM had 4.420-fold higher risk of death than those without (HR: 4.420, 95% CI: 1.371–14.246, p = 0.013). Higher ALT levels were also independently associated with mortality (p = 0.038). The prevalence of SPM and frailty was high in elderly patients with MM in our study. The development of SPM independently reduces survival in MM; however, frailty was not found to be independently associated with survival. Our results suggest the importance of individualized approaches in the management of patients with MM, particularly with regard to SPM development. |
format | Online Article Text |
id | pubmed-10297070 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102970702023-06-28 The Effects of Second Primary Malignancies and Frailty on Overall Survival and Mortality in Geriatric Turkish Patients with Multiple Myeloma Ipek, Yildiz Karademir, Nevra Yilmazer, Onur Yilmaz, Guven Curr Oncol Article The study aims to investigate second primary malignancy (SPM) development and frailty in Turkish geriatric patients with multiple myeloma (MM) and to assess the relationship between overall survival (OS) and various characteristics including SPM and frailty. Seventy-two patients diagnosed with and treated for MM were enrolled in the study. Frailty was determined by the IMWG Frailty Score. Fifty-three participants (73.6%) were found to have clinically-relevant frailty. Seven patients (9.7%) had SPM. Median follow-up was 36.5 (22–48.5) months, and 17 patients died during the follow-up period. Overall (OS) was 49.40 (45.01–53.80) months. Shorter OS was found in patients with SPM (35.29 (19.66–50.91) months) compared to those without (51.05 (46.7–55.4) months) (Kaplan–Meier; p = 0.018). The multivariate cox proportional hazards model revealed that patients with SPM had 4.420-fold higher risk of death than those without (HR: 4.420, 95% CI: 1.371–14.246, p = 0.013). Higher ALT levels were also independently associated with mortality (p = 0.038). The prevalence of SPM and frailty was high in elderly patients with MM in our study. The development of SPM independently reduces survival in MM; however, frailty was not found to be independently associated with survival. Our results suggest the importance of individualized approaches in the management of patients with MM, particularly with regard to SPM development. MDPI 2023-06-09 /pmc/articles/PMC10297070/ /pubmed/37366906 http://dx.doi.org/10.3390/curroncol30060423 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ipek, Yildiz Karademir, Nevra Yilmazer, Onur Yilmaz, Guven The Effects of Second Primary Malignancies and Frailty on Overall Survival and Mortality in Geriatric Turkish Patients with Multiple Myeloma |
title | The Effects of Second Primary Malignancies and Frailty on Overall Survival and Mortality in Geriatric Turkish Patients with Multiple Myeloma |
title_full | The Effects of Second Primary Malignancies and Frailty on Overall Survival and Mortality in Geriatric Turkish Patients with Multiple Myeloma |
title_fullStr | The Effects of Second Primary Malignancies and Frailty on Overall Survival and Mortality in Geriatric Turkish Patients with Multiple Myeloma |
title_full_unstemmed | The Effects of Second Primary Malignancies and Frailty on Overall Survival and Mortality in Geriatric Turkish Patients with Multiple Myeloma |
title_short | The Effects of Second Primary Malignancies and Frailty on Overall Survival and Mortality in Geriatric Turkish Patients with Multiple Myeloma |
title_sort | effects of second primary malignancies and frailty on overall survival and mortality in geriatric turkish patients with multiple myeloma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297070/ https://www.ncbi.nlm.nih.gov/pubmed/37366906 http://dx.doi.org/10.3390/curroncol30060423 |
work_keys_str_mv | AT ipekyildiz theeffectsofsecondprimarymalignanciesandfrailtyonoverallsurvivalandmortalityingeriatricturkishpatientswithmultiplemyeloma AT karademirnevra theeffectsofsecondprimarymalignanciesandfrailtyonoverallsurvivalandmortalityingeriatricturkishpatientswithmultiplemyeloma AT yilmazeronur theeffectsofsecondprimarymalignanciesandfrailtyonoverallsurvivalandmortalityingeriatricturkishpatientswithmultiplemyeloma AT yilmazguven theeffectsofsecondprimarymalignanciesandfrailtyonoverallsurvivalandmortalityingeriatricturkishpatientswithmultiplemyeloma AT ipekyildiz effectsofsecondprimarymalignanciesandfrailtyonoverallsurvivalandmortalityingeriatricturkishpatientswithmultiplemyeloma AT karademirnevra effectsofsecondprimarymalignanciesandfrailtyonoverallsurvivalandmortalityingeriatricturkishpatientswithmultiplemyeloma AT yilmazeronur effectsofsecondprimarymalignanciesandfrailtyonoverallsurvivalandmortalityingeriatricturkishpatientswithmultiplemyeloma AT yilmazguven effectsofsecondprimarymalignanciesandfrailtyonoverallsurvivalandmortalityingeriatricturkishpatientswithmultiplemyeloma |